PMV Pharmaceuticals Inc. (PMVP): Price and Financial Metrics
GET POWR RATINGS... FREE!
PMVP Stock Price Chart Interactive Chart >
PMVP Price/Volume Stats
Current price | $8.27 | 52-week high | $24.26 |
Prev. close | $8.27 | 52-week low | $7.57 |
Day low | $8.22 | Volume | 230,946 |
Day high | $8.42 | Avg. volume | 464,667 |
50-day MA | $9.11 | Dividend yield | N/A |
200-day MA | $12.50 | Market Cap | 377.65M |
PMV Pharmaceuticals Inc. (PMVP) Company Bio
PMV Pharmaceuticals, Inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.
Latest PMVP News From Around the Web
Below are the latest news stories about PMV PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PMVP as an investment opportunity.
Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect?The mean of analysts' price targets for PMV Pharmaceuticals, Inc. (PMVP) points to a 267.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceCRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference, taking place November 29 – December 1, 2022. The company will al |
15 Most Shorted Stocks Right NowIn this article, we discuss the 15 most shorted stocks right now. If you want to read about some more shorted stocks, go directly to 5 Most Shorted Stocks Right Now. The stock market has been volatile in the past few months as soaring inflation and rising rates combine to create an uncertain business environment […] |
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate HighlightsEnrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination trial with Merck evaluating PC14586 with KEYTRUDA® (pembrolizumab) on track to initiate in 2022 Biotech industry veteran Dr. Carol Gallagher appointed to Board of Directors CRANBURY, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology com |
We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
PMVP Price Returns
1-mo | 0.24% |
3-mo | -36.14% |
6-mo | -44.68% |
1-year | -47.66% |
3-year | N/A |
5-year | N/A |
YTD | -4.94% |
2022 | -62.34% |
2021 | -62.45% |
2020 | N/A |
2019 | N/A |
2018 | N/A |
Loading social stream, please wait...